Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Macular Degeneration Treatment Market is Worth US$11.4 Bn By 2026on September 6, 2019 at 4:14 am
The market is growing at striking CAGR around 6.6 % over the forecast time frame 2018 - 2026. Increase in age-related macular degeneration treatment (AMD) is expected to drive the growth of the global ...
- OpRegen appears well tolerated in dry AMDon September 5, 2019 at 11:08 am
COEUR D’ALENE, Idaho — In patients with dry age-related macular degeneration, the implantation of human embryonic stem cell-derived retinal pigment epithelial cells was mostly well tolerated, ...
- Age-related vision problems are commonon September 5, 2019 at 8:10 am
With aging adults, especially those with a family history of vision issues, age-related or not, as well as macular degeneration, regular visits to the eye doctor are recommended. “Eye issues can ...
- Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbioon September 4, 2019 at 7:20 am
RGNX), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD ...
- Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINAon September 4, 2019 at 2:30 am
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterized by the loss of vision of the middle of the visual field caused by degeneration of the central portion of ...
- Gyroscope Targets Age-Related Blindness with €55M Series Bon September 3, 2019 at 9:57 am
UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome ...
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Conon September 3, 2019 at 5:00 am
Results of Allegro’s Ex-U.S. Proof-of-Concept Trial with Integrin Regulator ALG-1007 for Dry Eye Disease Will Be Presented at the 37 th Congress of the ESCRS In June, Allegro announced topline results ...
- Wet Age-Related Macular Degeneration Market Forecast 2019-2024 - Positive Clinical Trial Results and Increasing Approvals for Pipeline Drugson August 27, 2019 at 9:09 am
The global wet age-related macular degeneration (AMD) market attained a size of $6.9 billion in 2018, and it is expected to reach $10.4 billion by 2024, advancing at a CAGR of 7.1% during the forecast ...
- Dry Age-Related Macular Degeneration Market Insights, Epidemiology and Market Forecast-2028on August 26, 2019 at 6:54 am
1. Age-related Macular Degeneration affects approximately 1.8 million Americans aged 40 years and older. 2. Approximately 85–90% of the cases of macular degeneration are the "dry" type. 3. Age-Related ...
via Bing News